Fusion Antibodies

Fusion Antibodies are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects.

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include the custom expression and purification of recombinant proteins for pre-clinical models, antibody sequencing, antibody engineering, antibody humanisation and cGMP services.

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.